Sales of Biocon’s itolizumab surge as phase-4 clinical trials begin
With Phase-4 clinical trials on, sales may see a further uptick if the data support it helps Covid-19 patients, said, experts. The data from market research firm AIOCD AWACS showed that volumes shot up seven times in August (350 units) from just 50 units in July when it received the approval. In June, the drug did not show sales.
Biocon’s repurposed psoriasis drug itolizumab has seen sevenfold jump in sales after it got an emergency use authorisation for Covid-19 treatment. The drug, however, is yet to be a part of the clinical management protocol of the health ministry for treatment of Covid-19, which implies that the government has not yet recommended it as an effective treatment.
In India, itolizumab, known by the brand name Alzumab With Phase-4 clinical trials on, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000. In a few cases, a patient might need two more vials.
Tap To Explore More : NCBI